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Xenon in the treatment of panic 
disorder: an open label study
Alexander Dobrovolsky1,2,3, Thomas E. Ichim3*, Daqing Ma4, Santosh Kesari5 and Vladimir Bogin3
Abstract 
Background: Current treatments of panic disorder (PD) are limited by adverse effects, poor efficacy, and need for 
chronic administration. The established safety profile of subanesthetic concentrations of xenon gas, which is known 
to act as a glutamate subtype NMDA receptor antagonist, coupled with preclinical studies demonstrating its effects in 
other anxiety related conditions, prompted us to evaluate its feasibility and efficacy in treatment of patients with PD.
Methods: An open-label clinical trial of xenon–oxygen mixture was conducted in 81 patients with PD; group 1 con-
sisting of patients only with PD (N = 42); and group 2 patients with PD and other comorbidities (N = 39).
Results: Based on the analysis of the results of a number of psychometric scales used in this study (SAS, HADS, 
CGI), several conclusions can be made: (1) xenon is a potentially effective modality in acute treatment of PD; (2) an 
anti-panic effect of xenon administration persists for at least 6 months after the completion of the active phase of 
treatment; (3) xenon inhalation is well tolerated, with the drop-out rates being much lower than that of conventional 
pharmacotherapy (5.8% vs. 15%); (4) the severity of depressive disorders that frequently accompany PD can be signifi-
cantly reduced with the use of xenon; (5) xenon may be considered as an alternative to benzodiazepines in conjunc-
tion with cognitive-behavioral therapy as a safe modality in treatment of anxiety disorder.
Conclusions: These data support the need for randomized double-blind clinical trials to further study xenon-based 
interventions.
Trial registration This clinical trial was retrospectively registered on April 14th, 2017 as ISRCTN15184285 in the ISRCTN 
database.
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Background
One of the most common anxiety disorders is panic dis-
order (PD), with a 12  month prevalence in the US and 
in Europe estimated at 1.8 and 2.7% of the population, 
respectively [1, 2]; the main clinical feature of which is an 
unexpected panic attack (PA) that arises in the absence 
of any situational or emotional triggers, reaching its peak 
intensity within minutes, that is manifested by intense 
physical and cognitive symptoms, such as fear of recur-
rence, general health concerns, and behavioral changes 
[3, 4]. In addition to spontaneous PA, its other forms 
include situationally predisposed PA, “symptomatically 
mild” (“minor”) PA [5], in which less than 4 out of 13 
symptoms listed in the DSM-IV are present, and “noctur-
nal” panic attacks that occur during phase 2 of the sleep 
cycle [6].
Panic disorder in its “pure” form is found only in 24.6% 
of cases, in 36.7% of cases it is accompanied by a comor-
bid disorder, in 13.3% —by 2, and in 23.5%—by 3 or more 
mental disorders, mainly anxiety and diseases of depres-
sive spectrum [7]. Lecrubier et  al. had shown that indi-
viduals with isolated panic attacks are more prone to the 
development of depression (45.6%) than to development 
of a panic disorder [8].
To date, the greatest clinical evidence of efficacy in 
the treatment of PD has been demonstrated with the 
use of selective serotonin reuptake inhibitors (SSRIs), 
serotonin–norepinephrine reuptake inhibitors (SNRIs) 
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(drugs of first choice) and benzodiazepine tranquiliz-
ers (drugs of second choice) [9]. Disadvantages of SSRIs/
SNRIs therapy include delayed onset of therapeutic 
effect (2–6 weeks), and side effects at the start of therapy, 
which can limit its use in the treatment of PD, especially 
given the importance of achievement of rapid anxiolytic 
effect [10, 11]. While benzodiazepines have immediate 
onset of action, their side effect profile is significant and 
includes excessive sedation, slow reaction time, dizziness, 
and possible paradoxical reactions such as anxiety [12]. 
In addition, knowledge of benzodiazepines’ high risk of 
dependence [13, 14], often forces patients with PD lead-
ing an active lifestyle, to seek other, alternative methods 
of treatment. These side effects in themselves can exacer-
bate PD and become the triggers of panic attacks. Histor-
ically, 18% of patients receiving SSRIs and 15% of patients 
receiving benzodiazepines drop-out from clinical studies 
[8]. To our knowledge, the contemporary scientific lit-
erature contains practically no data on the treatment of 
refractory PD, where both first- and second-line treat-
ment options are ineffective. Additionally, there are fre-
quent clinical scenarios where PD exists concomitantly 
with other psychiatric comorbidities or where panic 
attacks don’t reach the diagnostic threshold of a panic 
disorder, but nevertheless have a significant impact on 
the course of the underlying disease and impair social 
functioning. Thus, the search for an alternative treatment 
modality with non-habit forming anxiolytic effect and 
minimal side effects aimed at rapid relief of panic attacks 
represents an urgent unmet need in the treatment of PD.
Anxiety symptoms can occur in a variety of mental 
and substance abuse disorders. In particular, “neuroveg-
etative” (poor sleep, sweating, loss of appetite, tremors, 
high blood pressure), anxiety and depressive symptoms 
are well established components of opioid and alcohol 
dependence and withdrawal, which are currently being 
treated with psychotropic drugs, including benzodiaz-
epines, valproate and antiadrenergic agents [8, 15].
Xenon is a monatomic inert gas with very low chemical 
reactivity. It is colorless, odorless and heavy. Xenon has 
a very low blood-gas partition coefficient, rapidly pen-
etrates the blood–brain barrier, which makes it an ideal 
general anesthetic. Xenon is a competitive N-methyl-
d-aspartate (NMDA) receptor antagonist, which it 
exhibits through binding to glycine site of glutamater-
gic NMDA receptor [16]. In addition, xenon reduces 
excitatory neurotransmission through downregulation 
of 5-HT3 [17], nicotinic acetylcholine [18], potassium 
channel [19], HCN channel [20], and AMPA [21]. It also 
increases inhibitory neurotransmission by upregulating 
TREK1 [22]. Of relevance to fear associated conditions 
such as PD, the role of NMDA receptors in modulation 
of fear memories has previously been suggested [23]. 
Accordingly, Meloni et al. demonstrated that administra-
tion of xenon gas in a rat model of fear memory recon-
solidation—a state in which recalled memories become 
susceptible to modification, reduced conditioned fear 
induced freezing [24].
Other psychiatric uses of xenon have been explored, for 
example, promising results on the use of inhaled xenon in 
opioid and alcohol withdrawal states, based on its phar-
macokinetic effects have been reported [25–28]; in par-
ticular, its anti-stress properties, decreased sensitivity to 
pain and improved adaptation [29, 30]. However, there is 
paucity of research on the use of xenon outside of anes-
thesiology and addiction. According to some authors, its 
therapeutic properties are likely based on its effect on the 
glutamatergic system neuromodulation [31] via inhibi-
tion of NMDA receptors and reduction in binding of glu-
tamate [31–33]. It was also shown that xenon at a dose of 
30–50–70% in the gas mixture does not alter plasma con-
centrations of dopamine and norepinephrine, but causes 
a significant reduction of the level of adrenaline and cor-
tisol [34].
It should also be noted that due to the biochemical 
inertness xenon, it exhibits no acute or chronic toxicity 
[35], embryotoxic or teratogenic effects, it is non-aller-
genic [18, 33], and does not alter the integrity of brain 
structures [36].
In recent studies it was demonstrated that the glu-
tamatergic system plays a significant role in the regula-
tion of anxiety. In particular, blockade of glutamatergic 
transmission in the periaqueductal gray matter lead to 
restoration of normal behavior in animals, and glutamate 
antagonists exhibited anxiolytic properties in experimen-
tal conditions [37].
In addition, preclinical studies have shown that block-
ing the glycine site NMDA-glutamate receptors results 
in anxiolytic effects [38]. Some supporting evidence that 
implicates glutamate in the pathogenesis of anxiety dis-
orders stems from the efficacy of pregabalin, in which 
the mechanism of action is associated with inhibition of 
glutamate release [39]. Thus, on the basis of clinical data 
previously obtained from the use of xenon in anesthe-
siology and addiction medicine, as well as based on its 
receptor activity profile (reduction of glutamatergic neu-
rotransmission) it can be expected that xenon possesses 
an independent anti-anxiety effect. The preliminary expe-
rience of using xenon in the outpatient treatment of vari-
ous psychiatric and addictive diseases has been marked 
by its clear anxiolytic effect, which triggered our desire to 
study xenon’s effect on specific anxiety disorders. PD was 
selected because of its paroxysmal, easily quantifiable 
nature and a high degree of recurrence, and also because 
the “panic attack” phenomenon occurs widely in other 
anxiety states.
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The clinical study presented aimed to: (a) study efficacy 
and adverse effect profile of xenon in acute treatment 
as a monotherapy for “pure” PD; (b) assess efficacy and 
adverse effect profile of xenon in treatment of PD in the 
presence of other mental illness comorbidities; and (c) 
quantify the duration of xenon’s therapeutic effect.
Methods
Patients
This investigator-initiated study was performed under 
a prospective clinical trial protocol approved by the 
Institute of Mental Health and Addictology, which is 
accredited by the Ministry of Health of the Russian Fed-
eration to conduct clinical trials (#57689). Study con-
duct was in compliance with all ethical standards and 
good clinical practice. All study participants provided 
written informed consent prior to undergoing any pro-
tocol-related procedures. The study was registered at 
http://www.isrctn.com (number in process, application 
#32439). Ninety outpatients with a diagnosis of “panic 
disorder”  (F41.0) according to ICD-10 were enrolled 
through the Institute of Mental Health and Addictology. 
Five patients dropped out of the study due to minor side 
effects, predominantly lightheadedness and headaches, 
and 4 patients dropped out of the study for unspecified 
reasons. As the intention to treat analysis was not utilized 
due to the open label design of the study, 81 patients with 
PD (49 women and 32 men), mean age was 35.2  years 
(range 18–69) were studied. Patients were randomized 
into 2 groups: with “pure” PD (group 1) and “comorbid” 
PD, when it was co-diagnosed with other mental illnesses 
(group 2). All patients with isolated PD (group 1, n = 42) 
received monotherapy with xenon at the aforemen-
tioned schedule, while the majority of patients (94.9%) 
with PD and comorbid conditions, which were predomi-
nantly depression (group 2, n = 39), in addition to xenon 
administration continued treatment for comorbid psy-
chiatric disorders, which mainly consisted of antidepres-
sants (SSRIs and SNRIs). In these patients, the reason for 
xenon treatment was the increase in the frequency and 
severity of panic attacks despite ongoing treatment with 
stable pharmacotherapy of at least 3–6 months’ duration.
Xenon administration
Administration of xenon was performed through inhala-
tion of xenon–oxygen mixtures that were escalated from 
15%/85% to 30%/70% with titration increments of 5% per 
session. Each patient in the study underwent between 6 
and 7 treatments with xenon–oxygen mixture. The first 
three sessions were carried out daily and from session 
4 onward—every other day. The selected dosing regime 
and the composition of the gas mixtures were based on 
the historical evidence of safety of subanesthetic use of 
xenon in imaging [40–42].
Medical grade xenon (“medksenon”®, 99.9999%, manu-
facturer: Atommedcenter, Moscow, Russia) and medical 
grade oxygen in separate containers were admixed. Mix-
ing and administration of gases in preset concentration 
and volume was accomplished with the use of the medi-
cal device MAGi-AMTS1, which enables the operator to 
adjust the concentration of xenon in the gas mixture, and 
which contains the electronic flow meter with a software 
module that allows for such adjustments. Administra-
tion of xenon–oxygen mixture to the patient was carried 
out via a face mask. Patients were asked to slowly inhale, 
holding breath for 5–10 s; exhale into the loop and after 
35–40 s exhale outside the contour and breath in the new 
portion of gas mixture. Xenon inhalation lasted from 2.5 
to 4 min, and the xenon consumption was capped at 3.0 L 
per procedure. The patients were assessed subjectively by 
the provider, while the vital signs (pulse, blood pressure, 
oxygen saturation) were continuously monitored.
Patient assessment
Patients were evaluated after each xenon inhalation and 
at 30 and 180 days after completion of treatment. To this 
end, we employed clinical psychopathological and clini-
cal catamnestic methods, and psychometric scales that 
are widely used internationally to assess the treatment 
of mental disorders. Scale Assessment, Zung Self-Rat-
ing Anxiety Scale (SAS) was performed prior to start-
ing therapy (V1), and at 1 and 6 months after treatment. 
According to this scale, SAS index of less than 45 points 
corresponds to the normal value, 45–59—to mild-to-
moderate degree of anxiety, 60–74—to high degree of 
anxiety, more than 75—to an extremely high-level of 
anxiety. Hospital Anxiety and Depression Scale (Hos-
pital Anxiety and Depression Scale, HADS_T-anxiety 
subscale, HADS_D-Depression subscale) was used prior 
to the (V1), after the third (V3) and sixth (V6) xenon 
administrations. Categories for the assessment for each 
of the following subscales are as follows: 0–7 points—
normal (absence of reliable pronounced symptoms of 
anxiety/depression); 8–10 points—subclinical anxiety/
depression; 11 points and above—symptomatic anxiety/
depression. Clinical Global Impression Scale (CGI-I—
improvement subscale, CGI-S—severity of the disease 
subscale) was used before treatment and after each of 
the following 6 xenon treatments (V1, V2, V3, V4, V5, 
V6).
Statistical analysis of the results was carried out via 
statistical and analytical methods using Microsoft Excell 
2000 program and with Statistica statistical tools (http://
www.statsoft.com/, http://www.statsoft.ru/).
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Results
The two groups of patients, with “pure” PD (group 
1, n  =  42) and with “comorbid” PD (group 2, n  =  39) 
were well matched (Table  1). For patients in group 2 
the following comorbid disorders were most commonly 
observed: mixed anxiety-depressive disorder (43.6%), 
bipolar affective disorder (10.3%), recurrent depressive 
disorder (10.3%), obsessive–compulsive disorder (5.1%), 
and other nonpsychotic mental disorders (12.8%, heading 
F48).
Changes in the subscale of “anxiety” in Hospital Anxi-
ety and Depression Scale (HADS_T) are presented in 
Fig.  1. The total score on this scale in both groups cor-
responded to the level of “clinically severe anxiety” (17.7 
and 19.0, respectively), and showed a decrease (−4.6 and 
5.7 points, respectively) after 3 sessions (V3) of xenon 
administration (13.3 and 13.3, respectively). By the end 
of treatment (V6), the overall scores in both groups cor-
responded to the category of the “norm” for HADS_T 
Scale. Statistical analysis of the changes in SAS Scale 
using paired test samples is presented in Table 2.
Analysis of Clinical Global Impression Scale Improve-
ment Subscale (CGI-I) changes after the third treatment 
shows a more significant improvement with xenon treat-
ment (“marked improvement” on the CGI-I) in group 
1 than in group 2 (40.5 and 10.3%, respectively, when 
compared to baseline). This trend persisted after 6 treat-
ments: the indicator “very much improved” in patients 
with “pure” PD was 52.4%, while for those with “comor-
bid” PD it was only 12.8% (Table  3). According to the 
Clinical Global Impression Scale Severity of the Disease 
Subscale (CGI-S) (Table 4), before the start of treatment, 
both groups of patients demonstrated a pronounced 
degree of impairment: the indicator “significantly pro-
nounced disease” was at 90.5 and 87.2%, respectively. 
After the third procedure, reduction in the severity of 
disorders was more pronounced in group 1: the indi-
cator “moderately severe disease” was 48.7 and 11.9%, 
respectively. At the same time, upon completion of xenon 
treatments the differences between the two groups dis-
appeared and most patients in both groups reached the 
“borderline” level (82.1 and 88.1%, respectively).
Thus, by analyzing the changes in the indices of psy-
chometric scales (HADS_T, CGI-I, CGI-S) it can be con-
cluded that the use of xenon treatment in PD produced 
rapid onset of action, statistically significant clinical 
Table 1 Social and  demographic characteristics of  the 
patients
Group
“Pure” 
PD (n = 42)
“Comorbid” 
PD (n = 39)
Total (n = 81)
Age, years
 Mean 36.1 34.3 35.2
 Standard devia-
tion
12.90 12.20 12.52
 Median 32.0 33.0 33.0
 Minimum 19 18 18
 Maximum 69 68 69
Sex
 Male, n (%) 22 (52.4%) 10 (25.6%) 32 (39.5%)
 Female, n (%) 20 (47.6%) 29 (74.4%) 49 (60.5%)
Employment
 No, n (%) 19 (45.2%) 18 (46.2%) 37 (45.7%)
 Yes, n (%) 23 (54.8%) 21 (53.8%) 44 (54.3%)
Disease duration, months
 Mean 8.9 16.9 12.8
 Standard devia-
tion
5.28 7.54 7.60
 Median 6.0 18.0 12.0
 Minimum 3 3 3
 Maximum 18 24 24
Marriage status
 No, n (%) 16 (38.1%) 21 (53.8%) 37 (45.7%)
 Yes, n (%) 26 (61.9%) 18 (46.2%) 44 (54.3%)
Children
 No, n (%) 17 (40.5%) 21 (53.8%) 38 (46.9%)
 Yes, n (%) 25 (59.5%) 18 (46.2%) 43 (53.1%)
Fig. 1 Reduction in Anxiety Score on the HADS_T Scale after Xenon 
Administration. Patients with only PD (group 1, n = 42) and “comor-
bid” PD (group 2, n = 39) where administered 6–7 sessions of xenon 
inhalation as described in “Methods”. Analysis of HADS_T score was 
performed. Error bars indicate 95% CI
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improvement, and complete cessation of panic attacks 
after the 6th treatment.
Symptom changes on the SAS scale are presented 
in Fig.  2. The initial presentation in both groups 
corresponded to “high level of anxiety”(72.7 and 64.1, 
respectively). One month after treatment, all patients 
showed a decrease in the SAS total score, although it 
was more pronounced in group 1: 36.5 points (which 
Table 2 Results of statistical analysis of HADS_T assessments of changes from baseline (V1) using a paired t test for the 
evaluation visits within each patient group
Paired differences t df Sig. (2-tailed)
Mean Std. deviation Std. error mean 95% confidence interval
Lower Upper
Group 1
 HADS-T, V3 to HADS-T, V1 −4.595 3.379 .521 −5.648 −3.542 −8.813 41 .000
 HADS-T, V6 to HADS-T, V1 −11.214 3.440 .531 −12.286 −10.142 −21.129 41 .000
Group 2
 HADS-T, V3 to HADS-T, V1 −5.692 1.749 .280 −6.259 −5.125 −20.319 38 .000
 HADS-T, V6 to HADS-T, V1 −11.436 2.882 .461 −12.370 −10.502 −24.782 38 .000
Table 3 Changes in CGI-I Scale during treatment
Group
“Pure” PD (n = 42) “Comorbid” PD (n = 39) Total (n = 81)
n % n % n %
CGI-I, V2
 Marked improvement 5 11.9 5 12.8 10 12.3
 Minimal improvement 20 47.6 24 61.5 44 54.3
 No changes 15 35.7 10 25.6 25 30.9
 Minimal deterioration 1 2.4 0 .0 1 1.2
 Marked deterioration 1 2.4 0 .0 1 1.2
 Overall 42 100.0 39 100.0 81 100.0
CGI-I, V3
 Marked improvement 17 40.5 4 10.3 21 25.9
 Minimal improvement 23 54.8 27 69.2 50 61.7
 No changes 2 4.8 8 20.5 10 12.3
 Overall 42 100.0 39 100.0 81 100.0
CGI-I, V4
 Marked improvement 34 81.0 10 25.6 44 54.3
 Minimal improvement 8 19.0 25 64.1 33 40.7
 No changes 0 .0 4 10.3 4 4.9
 Overall 42 100.0 39 100.0 81 100.0
CGI-I, V5
 Very marked improvement 2 4.8 0 .0 2 2.5
 Marked improvement 40 95.2 24 61.5 64 79.0
 Minimal improvement 0 .0 15 38.5 15 18.5
 Overall 42 100.0 39 100.0 81 100.0
CGI-I, V6
 Very marked improvement 22 52.4 5 12.8 27 33.3
 Marked improvement 20 47.6 34 87.2 54 66.7
 Overall 42 100.0 39 100.0 81 100.0
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corresponds to “no anxiety”) against 46.8 points in group 
2 (“minimum degree of anxiety”). Furthermore, these 
parameters remained approximately at the same level 
throughout the study follow up (34.5 and 47.9, respec-
tively). Statistical analysis of changes in SAS scale using 
paired test samples are presented in Table 5.
As noted above, in the modern classifications, in addi-
tion to “major” episodes that meet the criteria of a panic 
attack based on the number of symptoms, “limited 
symptom” (“minor”) panic attacks have been described, 
which, nevertheless, have an impact on social function-
ing and quality of life. As seen in Fig. 3, the mean number 
of “major” panic attacks per month in group 2 was even 
greater than that of the group 1 (7.7 and 11.7, respectively), 
while the number of “minor” attacks were slightly higher in 
group 1, or patients with “pure” PD (44.8 and 41.7, respec-
tively). 6  months after treatment “major” panic attacks 
were absent in both groups, while “minor” panic attacks 
occurred in a very few cases (.3–1, respectively).
The results of SAS scales and lack of panic attacks after 
6  months of treatment indicate the sustained anxiolytic 
effect of xenon administration.
As has already been noted, most often encountered 
comorbid mental conditions in group 2 included depres-
sive disorders. The high degree of severity of depressive 
symptoms indicate that the traditional in these cases 
antidepressant therapy was ineffective. While the effect 
of xenon directly on depression is beyond the scope of 
Table 4 Changes in CGI-S Scale during treatment
Group
“Pure ”PD (n = 42) “Comorbid” PD (n = 39) Total (n = 81)
n % n % n %
CGI-S, V1
 Moderately expressed disease 4 10.3 1 2.4 5 6.2
 Significantly expressed disease 34 87.2 38 90.5 72 88.9
 Serious disease 1 2.6 3 7.1 4 4.9
 Total 39 100.0 42 100.0 81 100.0
CGI-S, V2
 Moderately expressed disease 19 48.7 1 2.4 20 24.7
 Significantly expressed disease 20 51.3 39 92.9 59 72.8
 Serious disease 0 .0 2 4.8 2 2.5
 Total 39 100.0 42 100.0 81 100.0
CGI-S, V3
 Moderately expressed disease 19 48.7 5 11.9 24 29.6
 Significantly expressed disease 20 51.3 37 88.1 57 70.4
 Total 39 100.0 42 100.0 81 100.0
CGI-S, V4
 Weakly expressed disease 0 .0 20 47.6 20 24.7
 Moderately expressed disease 20 51.3 22 52.4 42 51.9
 Significantly expressed disease 19 48.7 0 .0 19 23.5
 Total 39 100.0 42 100.0 81 100.0
CGI-S, V5
 Borderline state 0 .0 6 14.3 6 7.4
 Weakly expressed disease 1 2.6 36 85.7 37 45.7
 Moderately expressed disease 37 94.9 0 .0 37 45.7
 Significantly expressed disease 1 2.6 0 .0 1 1.2
 Total 39 100.0 42 100.0 81 100.0
CGI-S, V6
 Normal state 0 .0 5 11.9 5 6.2
 Borderline state 32 82.1 37 88.1 69 85.2
 Weakly expressed disease 7 17.9 0 .0 7 8.6
 Total 39 100.0 42 100.0 81 100.0
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this study, the analysis of HADS_T subscale “Depression” 
of HADS_D scale (Table 6) warrants some observations 
on this topic. According to HADS_D, “clinically severe 
depression” was absent in 66.7% of the patients in group 
1 before the start of treatment, while it was present in 
92.3% of group 2. After 3 xenon treatments it was absent 
in 90.5% of patients in group 1, but was still present in 
the majority of patients in group 2 (82.1%). By the end of 
the active phase of treatment “clinically severe depres-
sion” was negligible in patients of group 1 (2.4%), and it 
decreased to 46.2% in group 2.
Xenon therapy was generally well tolerated, side effects, 
mainly headache and dizziness, were rare and lead to 
only 5 patients dropping out from the study (5.8%). 
After carefully reviewing the data from these patients, 
it should be noted that four of them were found to have 
clinical symptoms of mild organic brain disease of vas-
cular origin (F06.71 heading ICD-10), which is indirectly 
confirmed by the results of head and neck Doppler ultra-
sound. It was previously demonstrated that inhalation of 
xenon can increase cerebral blood flow [6].
Discussion
Despite the fact that SSRIs, SNRIs and benzodiazepines 
have proven efficacy in the treatment of PD, the delayed 
onset of action for the former and the side effects and the 
risk of dependence for the latter limit its use in the most 
active cohort of patients with PD. In addition, there are 
currently insufficient data on the treatment of refractory 
PD and on effective augmentation strategies, as well as 
on the treatment PD with comorbid mental illnesses.
The inert gas xenon was first shown to possess anes-
thetic properties over 50  years ago [43]. Over the last 
10  years the interest in xenon as an inhalational anes-
thetic has increased due to several characteristics 
associated with its use: cardiovascular stability, rapid 
induction and emergence from anesthesia, and its anal-
gesic effects—all of which make it an ideal anesthetic 
[44]. As a result, xenon has become more routinely used 
as an anesthetic agent in Europe and Japan and has gar-
nered increasing interest in the United States although, 
primarily due to the higher cost of xenon as compared 
Fig. 2 Reduction of the Zung Self-Rating Anxiety Scale (SAS) Score 
Subsequent to Xenon Administration. Patients with only PD (group 1, 
n = 42) and “comorbid” PD (group 2, n = 39) where administered 6–7 
sessions of xenon inhalation as described in “Methods”. Analysis of 
SAS score was performed. Error bars indicate 95% CI
Table 5 Descriptive statistics for  the Zung Self-Rating Anxiety Scale (SAS) and  changes compared with  baseline (V1) 
for the evaluation visits and patient groups
Paired differences t df Sig. 
(2-tailed)
Mean Std.  
deviation
Std. error 
mean
95% confidence interval 
of differences
Lower Upper
Group 1
 Pair 1
  Zung after 1 month, V1 −36.131 3.205 .495 −37.130 −35.132 −73.048 41 .000
 Pair 2
  Zung after 6 months, V1 −38.214 4.049 .625 −39.476 −36.952 −61.158 41 .000
Group 2
 Pair 1
  Zung after 1 month, V1 −17.308 7.508 1.202 −19.742 −14.874 −14.395 38 .000
 Pair 2
  Zung after 6 months, V1 −16.154 7.562 1.211 −18.605 −13.702 −13.340 38 .000
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to other inhalational anesthetics, it has not yet received 
FDA approval. Evidence suggests that xenon’s biological 
effects may be mediated through its ability to potently 
block the NMDA receptors [45].
Furthermore, xenon has distinct advantages over other 
NMDA antagonists, such as ketamine, for future transla-
tion to the clinical setting. First, subsedative concentra-
tions of xenon that would sufficiently block the NMDA 
receptor without producing anesthesia could potentially 
be administered briefly in a safe and effective manner in 
the outpatient setting with minimal medical monitoring. 
Second, in contrast to existing NMDA receptor blockers 
like ketamine, xenon has been shown to inhibit NMDA 
receptor activity through competitive inhibition of the co-
agonist glycine at the glycine site of the NMDA receptor 
[45]—a mechanism devoid of psychotomimetic effects.
On the basis of the result of this study’s clinical and 
psychometric data with the use of scales assessing both 
the severity of anxiety (SAS, HADS_T), and evaluation 
of treatment effect in general (CGI-I, CGI-S), several pre-
liminary conclusions can be made.
Firstly, when using xenon as an acute treatment of PD, 
reduction in both frequency and severity of panic attacks 
and anxiety level was observed during the first three treat-
ment sessions, and by the end of treatment the vast number 
of patients experienced complete resolution of panic attacks 
Fig. 3 Changes in HADS D Scale (subscale “depression”) after Xenon 
Administration. Patients with only PD (group 1, n = 42) and “comor-
bid” PD (group 2, n = 39) where administered 6–7 sessions of xenon 
inhalation as described in “Methods”. Analysis of Analysis of HADS_T 
score was performed. Error bars indicate 95% CI
Table 6 Changes in  the frequency of  major and  minor 
panic attacks (per month)
Group
“Pure” 
PD (n = 42)
“Comorbid” 
PD (n = 39)
Total (n = 81)
The frequency of major panic attacks before treatment, times/month, V1
 n 42 39 81
 Mean 7.7 11.7 9.6
 Standard devia-
tion
7.85 8.27 8.24
 Percentile 25 1.0 4.0 2.0
 Median 3.0 12.0 7.0
 Percentile 75 16.0 16.0 16.0
 Minimum 1 1 1
 Maximum 24 28 28
The frequency of major panic attacks 6 months after treatment
 n 42 39 81
 Mean .0 .0 .0
 Standard devia-
tion
.0 .0 .0
 Percentile 25 .0 .0 .0
 Median .0 .0 .0
 Percentile 75 .0 .0 .0
 Minimum 0 0 0
 Maximum 0 0 0
The frequency of minor panic attacks before treatment, times/month, V1
 n 42 39 81
 Mean 44.8 41.7 43.3
 Standard devia-
tion
16.18 15.29 15.73
 Percentile 25 28.0 28.0 28.0
 Median 56.0 56.0 56.0
 Percentile 75 56.0 56.0 56.0
 Minimum 4 4 4
 Maximum 84 56 84
The frequency of minor panic attacks 6 months after treatment, times/
month
 n 42 39 81
 Mean .3 1.0 .6
 Standard devia-
tion
.46 2.64 1.89
 Percentile 25 .0 .0 .0
 Median .0 .0 .0
 Percentile 75 1.0 1.0 1.0
 Minimum 0 0 0
 Maximum 1 16 16
Changes minor panic attacks_V6_V1
 n 42 39 81
 Mean −44.5 −40.7 −42.7
 Standard devia-
tion
16.19 15.12 15.70
 Percentile 25 −56.0 −56.0 −56.0
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while anxiety symptoms decreased to a subclinical level. 
This conclusion is also true for patients with PD with comor-
bidities. Secondly, after treatment of both “pure” PD and PD 
with psychiatric comorbidities, anxiolytic effect of xenon 
was maintained for at least 6 months, which clinically mani-
fested by cessation of panic attacks. Thirdly, treatment with 
xenon was well tolerated, although it is possible that patients 
with symptoms of cerebral insufficiency may experience 
such adverse events as headache and dizziness. Fourthly, 
although the effect of xenon on depressive disorders was 
beyond the scope of this study, the analysis of the changes in 
HADS_D scale allows us to make a preliminary conclusion: 
in patients with PD and comorbid depressive symptoms 
xenon treatment can not only lead to improvement in anxi-
ety symptoms, but also to reduction of depression sever-
ity. In this sense, we see as highly relevant a conduct of the 
study on the use of xenon as an adjuvant therapy for those 
patients with depressive disorders and concomitant anxi-
ety (with anxious distress according to DSM-5), which have 
not sufficiently responded to treatment with conventional 
pharmacotherapy. Fifthly, the current first line of treatment 
of PD, in addition to pharmacotherapy, includes cognitive-
behavioral therapy (CBT) [7]. At the same time, in clinical 
practice, the use of CBT in patients with severe PD in the 
early stages is often hampered by the high intensity of the 
somatic symptoms of anxiety and hypochondriacal fears, for 
relief of which providers often resort to the use of benzodi-
azepines. This approach can affect cognitive function and 
impede effective personal involvement in psychotherapy. 
In this sense, xenon treatment may be a good alternative to 
benzodiazepine tranquilizers because of its good tolerability, 
rapidity of onset and its lack of addictive potential.
The main methodological limitation of this study is 
its open design. In order to determine the place xenon 
in the treatment of PD additional randomized, placebo-
controlled clinical trials of xenon and psychotropic sub-
stances used for the treatment of PD (SSRIs, SNRIs, 
benzodiazepines) are needed. The design of such stud-
ies should distinguish between direct anxiolytic effect of 
xenon and a potential placebo effect.
Conclusions
The present study is the first work on the use of xenon in 
panic disorder that can give impetus to a more intensive 
research into xenon’s place in the treatment of anxiety 
and depressive disorders as both the adjunct and a poten-
tial alternative to the currently used psychotropic phar-
macotherapy. Given the accepted use of subanesthetic 
concentrations of xenon in imaging, and established 
safety profile of concentrations similar to the ones uti-
lized in the current study, future investigation of xenon 
based therapeutics in prospective double blind placebo 
controlled trials is warranted.
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Group
“Pure” 
PD (n = 42)
“Comorbid” 
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Total (n = 81)
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 Percentile 75 −28.0 −27.0 −28.0
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